Opthea Limited Investor Relations Material
Latest events
Investor Day
Opthea Limited
Study Result
23 Mar, 2025
H1 2025
26 Feb, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Opthea Limited
Access all reports
Opthea Limited is a clinical-stage biopharmaceutical company based in Australia, specializing in the development and commercialization of innovative therapies primarily for eye diseases. The company's primary focus is on advancing its intellectual property portfolio, which encompasses Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3. These are aimed to be used in treating diseases associated with blood and lymphatic vessel growth as well as vascular leakage. The company is headquartered in South Yarra, Victoria, Australia, and its shares are listed on the NASDAQ and ASX.
Key slides for Opthea Limited
Investor Day
Opthea Limited
Investor Day
Opthea Limited
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
OPT
Country
🇦🇺 Australia